Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
140 hedge funds and large institutions have $771M invested in Alder Biopharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 58 increasing their positions, 32 reducing their positions, and 19 closing their positions.
81% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 32
42% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 19
6% more funds holding
Funds holding: 132 → 140 (+8)
4% less capital invested
Capital invested by funds: $803M → $771M (-$32.6M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
31% less call options, than puts
Call options by funds: $799K | Put options by funds: $1.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$19.8M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.53M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.15M |
| 4 |
Morgan Stanley
New York
|
+$4.14M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$28.5M |
| 2 |
Janus Henderson Group
London,
|
-$12.8M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$11M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.29M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.44M |
ALDR Hedge Fund Activity: Q4 2017 in Review
140 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q4 2017, worth a combined $771M — down 4.1% from $803M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ALDR positions and 19 closed out — a net gain of 8 holders — while 58 added to existing stakes and 32 trimmed.
The largest buyer was Palo Alto Investors, adding an estimated $19.8M. The largest seller was Fidelity Investments, cutting an estimated $28.5M.
- 140 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q4 2017, up from 132 in Q3 2017.
- Funds reported $771M of Alder Biopharmaceuticals stock for Q4 2017, down 4.1% quarter-over-quarter.
- 27 funds opened new Alder Biopharmaceuticals positions in Q4 2017 and 19 closed out, a net change of +8 holders.
- The largest Alder Biopharmaceuticals buyer in Q4 2017 was Palo Alto Investors, an estimated $19.8M added.
- The largest Alder Biopharmaceuticals seller in Q4 2017 was Fidelity Investments, an estimated $28.5M sold.
Based on aggregated 13F filings for Q4 2017.